Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes

Diabetes & Metabolism
M B ChristensenK Nørgaard

Abstract

The aim of the study was to evaluate the association between C-peptide levels, glycaemic variability and hypoglycaemia in patients with insulin-treated type 2 diabetes (T2D). A total of 98 patients with T2D treated with basal-bolus insulin were enrolled in a cross-sectional study. Glycaemic variability and hypoglycaemia were assessed from continuous glucose monitoring (CGM) data recorded over 6 days: Glycemic variability was assessed by calculating the mean coefficient of variation (CV), while hypoglycemia was defined as sensor glucose levels ≤ 3.9 mmol/L or < 3.0 mmol/L. Fasting C-peptide and fasting glucose were measured on day 1. Low levels of fasting C-peptide correlated with higher CV (r = -0.53, P < 0.0001). In a multivariate regression model with HbA1c, body mass index, diabetes duration and total daily insulin dose, only C-peptide was significantly associated with CV. Patients with ≥ 1 episode of hypoglycaemia had significantly lower median C-peptide levels than patients without hypoglycaemia (274 (136-620) pmol/L vs. 675 (445-1013) pmol/L, respectively; P = 0.0004). Also, 17 patients clinically diagnosed with T2D had detectable glutamic acid decarboxylase (GAD) antibodies (≥ 5 U/mL). These GAD-positive patients had sig...Continue Reading

Citations

Aug 28, 2020·Diabetes Technology & Therapeutics·Merete B ChristensenKirsten Nørgaard
Jun 22, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Markolf HanefeldJochen Seufert
Aug 8, 2021·International Journal of Molecular Sciences·Vadim V KlimontovAnton I Korbut
Sep 28, 2021·Frontiers in Endocrinology·Anne-Esther BreytonJulie-Anne Nazare

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

Diabetic Medicine : a Journal of the British Diabetic Association
W M KuhtreiberD L Faustman
Horumon to rinsho. Clinical endocrinology
T Kaneko
Annales de médecine interne
M Dorner
Horumon to rinsho. Clinical endocrinology
T Kaneko
© 2022 Meta ULC. All rights reserved